Trial Outcomes & Findings for First in Human Study of M4344 in Participants With Advanced Solid Tumors (NCT NCT02278250)

NCT ID: NCT02278250

Last Updated: 2023-03-16

Results Overview

An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal relationship with this treatment. Therefore, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, regardless if it is considered related to the medicinal product. Serious AE: AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs are defined as AEs that were reported or worsened on or after start of study drug dosing through the Safety Follow-up Visit. TEAEs included both serious TEAEs and non-serious TEAEs.

• Recruitment status: COMPLETED
• Study phase: PHASE1
• Target enrollment: 97 participants
• Primary outcome timeframe: up to safety follow-up visit (Week 124.9)
• Results posted on: 2023-03-16

Participant Flow

This study was planned to be conducted in multiple parts; Part A, Part A2, Part B1, Part A3 (Dose escalation), Part C1, Part C2, Part C3, Part C4, Part C5 and Part C6 (Dose expansion). On 10 December 2020, the Sponsor decided to discontinue the development of M4344 and stop enrollment of any new participants. Due to the low number of cohorts and participants, data were not summarized per Part (Part C1, C2 and C3). Also, optional Parts A3, C4, C5, and C6 were not conducted.

Participant milestones

Measure	Part A: M4344 10 mg BIW Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A2: M4344 100 mg BID Participants received M4344 at a dose of 100 mg orally twice daily (BID) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A2: M4344 150 mg QD Participants received M4344 at a dose of 150 mg orally once daily (QD) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A2: M4344 250 mg QD Participants received M4344 at a dose of 250 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A2: M4344 350 mg QD Participants received M4344 at a dose of 350 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part B1: M4344 350 mg + Carboplatin Participants received M4344 at a dose of 350 mg orally on Day 2 and Day 9 in combination with intravenous infusion of Carboplatin at a dose of Area under the concentration versus time curve 5 (AUC5) on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part B1: M4344 400 mg + Carboplatin Participants received M4344 at a dose of 400 mg orally on Day 2 and Day 9 in combination with intravenous infusion of Carboplatin at a dose of AUC5 on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part B1: M4344 500 mg + Carboplatin Participants received M4344 at a dose of 500 mg orally on Day 2 and Day 9 in combination with intravenous infusion of Carboplatin at a dose of AUC5 on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part C: M4344 250 mg QD Participants received M4344 at a dose of 250 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Overall Study STARTED	2	1	2	1	1	2	4	12	10	7	7	5	7	7	3	7	6	13
Overall Study COMPLETED	2	1	2	1	1	2	4	12	10	7	7	5	7	7	3	7	6	13
Overall Study NOT COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

First in Human Study of M4344 in Participants With Advanced Solid Tumors

Baseline characteristics by cohort

Measure	Part A: M4344 10 mg BIW n=2 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=1 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=2 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=1 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW n=1 Participants Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW n=2 Participants Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW n=4 Participants Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW n=12 Participants Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW n=10 Participants Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW n=7 Participants Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A2: M4344 100 mg BID n=7 Participants Participants received M4344 at a dose of 100 mg orally twice daily (BID) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A2: M4344 150 mg QD n=5 Participants Participants received M4344 at a dose of 150 mg orally once daily (QD) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A2: M4344 250 mg QD n=7 Participants Participants received M4344 at a dose of 250 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A2: M4344 350 mg QD n=7 Participants Participants received M4344 at a dose of 350 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part B1: M4344 350 mg + Carboplatin n=3 Participants Participants received M4344 at a dose of 350 mg orally on Day 2 and Day 9 in combination with intravenous infusion of Carboplatin at a dose of Area under the concentration versus time curve 5 (AUC5) on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part B1: M4344 400 mg + Carboplatin n=7 Participants Participants received M4344 at a dose of 400 mg orally on Day 2 and Day 9 in combination with intravenous infusion of Carboplatin at a dose of AUC5 on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part B1: M4344 500 mg + Carboplatin n=6 Participants Participants received M4344 at a dose of 500 mg orally on Day 2 and Day 9 in combination with intravenous infusion of Carboplatin at a dose of AUC5 on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part C: M4344 250 mg QD n=13 Participants Participants received M4344 at a dose of 250 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Total n=97 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=36 Participants	0 Participants n=36 Participants	0 Participants n=24 Participants	0 Participants n=135 Participants	0 Participants n=136 Participants	0 Participants n=44 Participants	0 Participants n=667 Participants
Age, Categorical Between 18 and 65 years	2 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	1 Participants n=4 Participants	1 Participants n=21 Participants	1 Participants n=8 Participants	2 Participants n=8 Participants	8 Participants n=24 Participants	7 Participants n=42 Participants	6 Participants n=42 Participants	5 Participants n=42 Participants	2 Participants n=42 Participants	5 Participants n=36 Participants	4 Participants n=36 Participants	2 Participants n=24 Participants	3 Participants n=135 Participants	5 Participants n=136 Participants	9 Participants n=44 Participants	64 Participants n=667 Participants
Age, Categorical >=65 years	0 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants	2 Participants n=8 Participants	4 Participants n=24 Participants	3 Participants n=42 Participants	1 Participants n=42 Participants	2 Participants n=42 Participants	3 Participants n=42 Participants	2 Participants n=36 Participants	3 Participants n=36 Participants	1 Participants n=24 Participants	4 Participants n=135 Participants	1 Participants n=136 Participants	4 Participants n=44 Participants	33 Participants n=667 Participants
Sex: Female, Male Female	1 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	2 Participants n=8 Participants	0 Participants n=8 Participants	8 Participants n=24 Participants	6 Participants n=42 Participants	4 Participants n=42 Participants	3 Participants n=42 Participants	2 Participants n=42 Participants	4 Participants n=36 Participants	2 Participants n=36 Participants	0 Participants n=24 Participants	2 Participants n=135 Participants	3 Participants n=136 Participants	6 Participants n=44 Participants	45 Participants n=667 Participants
Sex: Female, Male Male	1 Participants n=5 Participants	0 Participants n=7 Participants	2 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	0 Participants n=8 Participants	4 Participants n=8 Participants	4 Participants n=24 Participants	4 Participants n=42 Participants	3 Participants n=42 Participants	4 Participants n=42 Participants	3 Participants n=42 Participants	3 Participants n=36 Participants	5 Participants n=36 Participants	3 Participants n=24 Participants	5 Participants n=135 Participants	3 Participants n=136 Participants	7 Participants n=44 Participants	52 Participants n=667 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=36 Participants	0 Participants n=36 Participants	0 Participants n=24 Participants	0 Participants n=135 Participants	0 Participants n=136 Participants	0 Participants n=44 Participants	0 Participants n=667 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	2 Participants n=5 Participants	1 Participants n=7 Participants	2 Participants n=5 Participants	1 Participants n=4 Participants	1 Participants n=21 Participants	2 Participants n=8 Participants	4 Participants n=8 Participants	12 Participants n=24 Participants	9 Participants n=42 Participants	5 Participants n=42 Participants	6 Participants n=42 Participants	4 Participants n=42 Participants	7 Participants n=36 Participants	6 Participants n=36 Participants	2 Participants n=24 Participants	4 Participants n=135 Participants	5 Participants n=136 Participants	12 Participants n=44 Participants	85 Participants n=667 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	1 Participants n=42 Participants	2 Participants n=42 Participants	1 Participants n=42 Participants	1 Participants n=42 Participants	0 Participants n=36 Participants	1 Participants n=36 Participants	1 Participants n=24 Participants	3 Participants n=135 Participants	1 Participants n=136 Participants	1 Participants n=44 Participants	12 Participants n=667 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=36 Participants	0 Participants n=36 Participants	0 Participants n=24 Participants	0 Participants n=135 Participants	0 Participants n=136 Participants	0 Participants n=44 Participants	0 Participants n=667 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=36 Participants	0 Participants n=36 Participants	0 Participants n=24 Participants	0 Participants n=135 Participants	1 Participants n=136 Participants	0 Participants n=44 Participants	1 Participants n=667 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=36 Participants	0 Participants n=36 Participants	0 Participants n=24 Participants	0 Participants n=135 Participants	0 Participants n=136 Participants	0 Participants n=44 Participants	0 Participants n=667 Participants
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	1 Participants n=42 Participants	0 Participants n=36 Participants	0 Participants n=36 Participants	0 Participants n=24 Participants	0 Participants n=135 Participants	0 Participants n=136 Participants	0 Participants n=44 Participants	2 Participants n=667 Participants
Race (NIH/OMB) White	2 Participants n=5 Participants	1 Participants n=7 Participants	2 Participants n=5 Participants	1 Participants n=4 Participants	1 Participants n=21 Participants	1 Participants n=8 Participants	4 Participants n=8 Participants	12 Participants n=24 Participants	8 Participants n=42 Participants	5 Participants n=42 Participants	4 Participants n=42 Participants	2 Participants n=42 Participants	7 Participants n=36 Participants	6 Participants n=36 Participants	2 Participants n=24 Participants	4 Participants n=135 Participants	3 Participants n=136 Participants	12 Participants n=44 Participants	77 Participants n=667 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=36 Participants	0 Participants n=36 Participants	0 Participants n=24 Participants	0 Participants n=135 Participants	0 Participants n=136 Participants	0 Participants n=44 Participants	0 Participants n=667 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	2 Participants n=42 Participants	2 Participants n=42 Participants	3 Participants n=42 Participants	2 Participants n=42 Participants	0 Participants n=36 Participants	1 Participants n=36 Participants	1 Participants n=24 Participants	3 Participants n=135 Participants	2 Participants n=136 Participants	1 Participants n=44 Participants	17 Participants n=667 Participants

PRIMARY outcome

Timeframe: up to safety follow-up visit (Week 124.9)

Population: The safety analysis set (SAF) included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg.

An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal relationship with this treatment. Therefore, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, regardless if it is considered related to the medicinal product. Serious AE: AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs are defined as AEs that were reported or worsened on or after start of study drug dosing through the Safety Follow-up Visit. TEAEs included both serious TEAEs and non-serious TEAEs.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=2 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=1 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=2 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=1 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW n=1 Participants Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW n=2 Participants Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW n=4 Participants Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW n=12 Participants Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW n=10 Participants Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW n=7 Participants Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)	2 Participants	1 Participants	2 Participants	1 Participants	1 Participants	2 Participants	4 Participants	12 Participants	10 Participants	7 Participants

PRIMARY outcome

Timeframe: up to safety follow-up visit (Week 124.9)

Population: The safety analysis set (SAF) included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg.

Laboratory parameters: hematology and chemistry. Blood samples were collected for analysis of following hematology parameters: Hemoglobin, Erythrocytes, mean corpuscular hemoglobin (MCH), MCH concentration, Mean corpuscular volume, Reticulocytes, Platelets, Leukocytes, Eosinophils, Basophils, Neutrophils, Lymphocytes, Monocytes. Blood samples were collected for analysis of following chemistry parameters: Glucose, Blood urea nitrogen/Urea, Creatinine, Sodium, Potassium, Calcium, Chloride, Magnesium, Bicarbonate, Inorganic phosphate, Total bilirubin, Direct bilirubin, Total protein, Albumin, Creatine kinase, Alkaline phosphatase, Aspartate aminotransferase, Alanine aminotransferase, Lactate dehydrogenase, Uric acid, Thyroid stimulating hormone. Number of participants with Grade 3 or 4 (>20% of total) in laboratory parameters were reported as per NCI-CTCAE v4.0 graded from Grade 1 to 5. Grade 1: Mild, Grade 2: Moderate; Grade 3: Severe. Grade 4: Life-threatening and Grade 5: Death.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=2 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=1 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=2 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=1 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW n=1 Participants Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW n=2 Participants Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW n=4 Participants Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW n=12 Participants Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW n=10 Participants Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW n=7 Participants Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A: Number of Participants With Grade 3 or 4 (Greater Than [>] 20 Percent [%] of Total) in Laboratory Parameters Based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v4.0) Hematology	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Part A: Number of Participants With Grade 3 or 4 (Greater Than [>] 20 Percent [%] of Total) in Laboratory Parameters Based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v4.0) Total Bilirubin	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	5 Participants	6 Participants	4 Participants

PRIMARY outcome

Timeframe: up to safety follow-up visit (Week 124.9)

Population: The safety analysis set (SAF) included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg.

Vital signs included body temperature, heart rate, systolic and diastolic blood pressure and respiration rate. Number of participants with clinically relevant findings in vital signs were reported. Clinical relevance was decided by Investigator.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=2 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=1 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=2 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=1 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW n=1 Participants Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW n=2 Participants Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW n=4 Participants Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW n=12 Participants Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW n=10 Participants Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW n=7 Participants Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A: Number of Participants With Clinically Relevant Findings in Vital Signs	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants

PRIMARY outcome

Timeframe: up to safety follow-up visit (Week 124.9)

Population: The safety analysis set (SAF) included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg.

ECG parameters included PR interval, RR interval, QT interval, QRS duration, QTc intervals (derived using Fridericia's correction method) and heart rate. A 12-lead ECG was recorded with the participant in a supine position after a rest of at least 5 minutes using an ECG machine. Clinical significance was decided by investigator. Number of participants with clinically significant abnormalities in 12-Lead ECGs were reported.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=2 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=1 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=2 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=1 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW n=1 Participants Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW n=2 Participants Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW n=4 Participants Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW n=12 Participants Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW n=10 Participants Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW n=7 Participants Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A: Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECGs)	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	1 Participants

PRIMARY outcome

Timeframe: up to Cycle 1 (each cycle is of 21 days)

Population: Dose Limiting Toxicity (DLT) Evaluable Set: included all enrolled participants who received at least 1 dose of M4344 and either: Experienced a DLT before the end of Cycle 1 or Received at least 80% of scheduled M4344 doses through the end of Cycle 1.

MTD as per NCI-CTCAE v4.0 is defined as highest dose for a given schedule at which there is no more than 1 dose- limiting toxicity (DLT) in 6 participants. DLT: as related/possibly drug-related: Neutropenia Grade (Gr)4 for > 7 days duration/requiring hemopoietic growth factors; Febrile neutropenia; Infection with Gr3/4 neutropenia; Thrombocytopenia Gr3; Thrombocytopenia Gr4 for > 7 days duration/requiring hemopoietic growth factors; Gr3/4 toxicity to organs other than bone marrow; Gr3/4 increase in bilirubin unless increase is due to inhibition of bilirubin glucuronidation; Death due to drug-related complications; Cardiac: QTc prolongation, Gr2/greater ventricular arrhythmia, severe sustained/symptomatic sinus bradycardia, persistent supraventricular arrhythmia, Symptoms suggestive of congestive heart failure, Troponin-T level consistent with myocardial infarction; drug-related toxicity causes interruption of treatment for > 2 weeks.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=42 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A: Maximum Tolerated Dose (MTD) of M4344 Administered Twice Weekly (BIW)	NA milligrams (mg) MTD not determined as development focus of the study shifted to daily monotherapy dosing (Part A2).	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: up to safety follow-up visit (Week 39)

Population: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg.

An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal relationship with this treatment. Therefore, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, regardless if it is considered related to the medicinal product. Serious AE: AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs are defined as AEs that were reported or worsened on or after start of study drug dosing through the Safety Follow-up Visit. TEAEs included both serious TEAEs and non-serious TEAEs.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=7 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=5 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=7 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=7 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)	7 Participants	5 Participants	7 Participants	7 Participants	—	—	—	—	—	—

PRIMARY outcome

Timeframe: up to safety follow-up visit (Week 39)

Population: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg.

Laboratory parameters: hematology and chemistry. Blood samples were collected for analysis of following hematology parameters: Hemoglobin, Erythrocytes, mean corpuscular hemoglobin (MCH), MCH concentration, Mean corpuscular volume, Reticulocytes, Platelets, Leukocytes, Eosinophils, Basophils, Neutrophils, Lymphocytes, Monocytes. Blood samples were collected for analysis of following chemistry parameters: Glucose, Blood urea nitrogen/Urea, Creatinine, Sodium, Potassium, Calcium, Chloride, Magnesium, Bicarbonate, Inorganic phosphate, Total bilirubin, Direct bilirubin, Total protein, Albumin, Creatine kinase, Alkaline phosphatase, Aspartate aminotransferase, Alanine aminotransferase, Lactate dehydrogenase, Uric acid, Thyroid stimulating hormone. Number of participants with Grade 3 or 4 (>20% of total) in laboratory parameters were reported as per NCI-CTCAE v5.0 graded from Grade 1 to 5. Grade 1: Mild, Grade 2: Moderate; Grade 3: Severe. Grade 4: Life-threatening and Grade 5: Death.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=7 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=5 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=7 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=7 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A2: Number of Participants With Grade 3 or 4 (Greater Than [>] 20 Percent [%] of Total) in Laboratory Parameters Based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v5.0) Low lymphocytes	1 Participants	1 Participants	2 Participants	3 Participants	—	—	—	—	—	—
Part A2: Number of Participants With Grade 3 or 4 (Greater Than [>] 20 Percent [%] of Total) in Laboratory Parameters Based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v5.0) Total Bilirubin	3 Participants	2 Participants	3 Participants	3 Participants	—	—	—	—	—	—
Part A2: Number of Participants With Grade 3 or 4 (Greater Than [>] 20 Percent [%] of Total) in Laboratory Parameters Based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v5.0) Aspartate Aminotransferase	2 Participants	1 Participants	0 Participants	4 Participants	—	—	—	—	—	—
Part A2: Number of Participants With Grade 3 or 4 (Greater Than [>] 20 Percent [%] of Total) in Laboratory Parameters Based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v5.0) Alanine Aminotransferase	2 Participants	2 Participants	0 Participants	3 Participants	—	—	—	—	—	—

PRIMARY outcome

Timeframe: up to safety follow-up visit (Week 39)

Population: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg.

Vital signs included body temperature, heart rate, systolic and diastolic blood pressure and respiration rate. Number of participants with clinically relevant findings were reported. Clinical relevance was decided by Investigator.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=7 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=5 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=7 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=7 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A2: Number of Participants With Clinically Relevant Findings in Vital Signs	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—

PRIMARY outcome

Timeframe: up to safety follow-up visit (Week 39)

Population: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg.

ECG parameters included PR interval, RR interval, QT interval, QRS duration, QTc intervals (derived using Fridericia's correction method) and heart rate. A 12-lead ECG was recorded with the participant in a supine position after a rest of at least 5 minutes using an ECG machine. Clinical Significance was determined by investigator. Number of participants with clinically significant abnormalities in 12-lead ECGs were reported.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=7 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=5 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=7 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=7 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A2: Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECGs)	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—

PRIMARY outcome

Timeframe: up to Cycle 1 (each cycle is of 21 days)

Population: DLT evaluable set included all enrolled participants who received at least one dose of M4344 and either: Experienced a DLT before the end of Cycle 1 or Received at least 80% of scheduled M4344 doses through the end of Cycle 1.

MTD as per NCI-CTCAE v5.0 is defined as highest dose for a given schedule at which there is no more than 1 dose- limiting toxicity (DLT) in 6 participants. DLT: as related/possibly drug-related: Neutropenia Grade (Gr)4 for > 7 days duration/requiring hemopoietic growth factors; Febrile neutropenia; Infection with Gr3/4 neutropenia; Thrombocytopenia Gr3; Thrombocytopenia Gr4 for > 7 days duration/requiring hemopoietic growth factors; Gr3/4 toxicity to organs other than bone marrow; Gr3/4 increase in bilirubin unless increase is due to inhibition of bilirubin glucuronidation; Death due to drug-related complications; Cardiac: QTc prolongation, Gr2/greater ventricular arrhythmia, severe sustained/symptomatic sinus bradycardia, persistent supraventricular arrhythmia, Symptoms suggestive of congestive heart failure, Troponin-T level consistent with myocardial infarction; drug-related toxicity causes interruption of treatment for > 2 weeks.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=26 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A2: Maximum Tolerated Dose (MTD) of M4344 Administered With a Dose Dense Schedule	250 mg	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: up to Safety follow-up (Week 92.3)

Population: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg.

An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal relationship with this treatment. Therefore, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, regardless if it is considered related to the medicinal product. Serious AE: AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs are defined as AEs that were reported or worsened on or after start of study drug dosing through the Safety Follow-up Visit. TEAEs included both serious TEAEs and non-serious TEAEs.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=3 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=7 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=6 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part B1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)	3 Participants	7 Participants	6 Participants	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: up to Safety follow-up (Week 92.3)

Population: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg.

Laboratory parameters: hematology and chemistry. Blood samples were collected for analysis of following hematology parameters: Hemoglobin, Erythrocytes, mean corpuscular hemoglobin (MCH), MCH concentration, Mean corpuscular volume, Reticulocytes, Platelets, Leukocytes, Eosinophils, Basophils, Neutrophils, Lymphocytes, Monocytes. Blood samples were collected for analysis of following chemistry parameters: Glucose, Blood urea nitrogen/Urea, Creatinine, Sodium, Potassium, Calcium, Chloride, Magnesium, Bicarbonate, Inorganic phosphate, Total bilirubin, Direct bilirubin, Total protein, Albumin, Creatine kinase, Alkaline phosphatase, Aspartate aminotransferase, Alanine aminotransferase, Lactate dehydrogenase, Uric acid, Thyroid stimulating hormone. Number of participants with Grade 3 or 4 (>20% of total) in laboratory parameters were reported as per NCI-CTCAE v4.0 graded from Grade 1 to 5. Grade 1: Mild, Grade 2: Moderate; Grade 3: Severe. Grade 4: Life-threatening and Grade 5: Death.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=3 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=7 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=6 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part B1: Number of Participants With Grade 3 or 4 (Greater Than [>] 20 Percent [%] of Total) in Laboratory Parameters Based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v4.0) Low Leukocytes	0 Participants	1 Participants	4 Participants	—	—	—	—	—	—	—
Part B1: Number of Participants With Grade 3 or 4 (Greater Than [>] 20 Percent [%] of Total) in Laboratory Parameters Based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v4.0) Low lymphocytes	1 Participants	3 Participants	1 Participants	—	—	—	—	—	—	—
Part B1: Number of Participants With Grade 3 or 4 (Greater Than [>] 20 Percent [%] of Total) in Laboratory Parameters Based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v4.0) Chemistry	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—
Part B1: Number of Participants With Grade 3 or 4 (Greater Than [>] 20 Percent [%] of Total) in Laboratory Parameters Based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v4.0) Neutrophils	1 Participants	1 Participants	5 Participants	—	—	—	—	—	—	—
Part B1: Number of Participants With Grade 3 or 4 (Greater Than [>] 20 Percent [%] of Total) in Laboratory Parameters Based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v4.0) Platelets	1 Participants	3 Participants	3 Participants	—	—	—	—	—	—	—
Part B1: Number of Participants With Grade 3 or 4 (Greater Than [>] 20 Percent [%] of Total) in Laboratory Parameters Based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v4.0) Low hemoglobin	1 Participants	4 Participants	1 Participants	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: up to Safety follow-up (Week 92.3)

Population: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg.

Vital signs included body temperature, heart rate, systolic and diastolic blood pressure and respiration rate. Number of participants with clinically relevant findings in vital signs were reported. Clinical relevance was decided by Investigator.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=3 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=7 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=6 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part B1: Number of Participants With Clinically Relevant Findings in Vital Signs	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: up to Safety follow-up (Week 92.3)

Population: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg.

ECG parameters included PR interval, RR interval, QT interval, QRS duration, QTc intervals (derived using Fridericia's correction method) and heart rate. A 12-lead ECG was recorded with the participant in a supine position after a rest of at least 5 minutes using an ECG machine. Clinical significance was determined by Investigator. Number of participants with clinically significant abnormalities in 12-lead ECGs were reported.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=3 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=7 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=6 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part B1: Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECGs)	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: up to Cycle 1 (each cycle is of 21 days)

Population: DLT evaluable set included all enrolled participants who received at least one dose of M4344 and either: Experienced a DLT before the end of Cycle 1 or Received Carboplatin dose on Day 1 and M4344 dose on Days 2 and 9.

MTD as per NCI-CTCAE v4.0 is defined as highest dose for a given schedule at which there is no more than 1 dose- limiting toxicity (DLT) in 6 participants. DLT: as related/possibly drug-related: Neutropenia Grade (Gr)4 for > 7 days duration/requiring hemopoietic growth factors; Febrile neutropenia; Infection with Gr3/4 neutropenia; Thrombocytopenia Gr3; Thrombocytopenia Gr4 for > 7 days duration/requiring hemopoietic growth factors; Gr3/4 toxicity to organs other than bone marrow; Gr3/4 increase in bilirubin unless increase is due to inhibition of bilirubin glucuronidation; Death due to drug-related complications; Cardiac: QTc prolongation, Gr2/greater ventricular arrhythmia, severe sustained/symptomatic sinus bradycardia, persistent supraventricular arrhythmia, Symptoms suggestive of congestive heart failure, Troponin-T level consistent with myocardial infarction; drug-related toxicity causes interruption of treatment for > 2 weeks.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=16 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part B1: Maximum Tolerated Dose (MTD) of M4344 (Monotherapy) Administered in Combination With Carboplatin	NA mg MTD not determined as development focus of the study shifted to daily monotherapy dosing (Part A2).	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: up to Safety follow-up (Week 31.1)

Population: The SAF included all participants who received at least one dose of study drug.

AE: any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal relationship with this treatment. Therefore, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom/disease temporally associated with use of a medicinal product, regardless if it is considered related to medicinal product. Serious AE: AE that resulted in any of following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs: AEs that were reported/worsened on/after start of study drug dosing through the Safety Follow-up Visit. TEAEs included both serious TEAEs and non-serious TEAEs. Treatment related AEs: reasonably related to the study drug/study treatment. AE could medically (pharmacologically/clinically) be attributed to the study drug/study treatment under study in this clinical study protocol.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=13 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part C: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment Related AEs According to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0 Participants with TEAEs	13 Participants	—	—	—	—	—	—	—	—	—
Part C: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment Related AEs According to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0 Participants with Treatment related AEs	13 Participants	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: up to Safety follow-up (Week 31.1)

Population: The SAF included all participants who received at least one dose of study drug.

Laboratory parameters: hematology and chemistry. Blood samples were collected for analysis of following hematology parameters: Hemoglobin, Erythrocytes, mean corpuscular hemoglobin (MCH), MCH concentration, Mean corpuscular volume, Reticulocytes, Platelets, Leukocytes, Eosinophils, Basophils, Neutrophils, Lymphocytes, Monocytes. Blood samples were collected for analysis of following chemistry parameters: Glucose, Blood urea nitrogen/Urea, Creatinine, Sodium, Potassium, Calcium, Chloride, Magnesium, Bicarbonate, Inorganic phosphate, Total bilirubin, Direct bilirubin, Total protein, Albumin, Creatine kinase, Alkaline phosphatase, Aspartate aminotransferase, Alanine aminotransferase, Lactate dehydrogenase, Uric acid, Thyroid stimulating hormone. Number of participants with Grade 3 or 4 (>20% of total) in laboratory parameters were reported as per NCI-CTCAE v5.0 graded from Grade 1 to 5. Grade 1: Mild, Grade 2: Moderate; Grade 3: Severe. Grade 4: Life-threatening and Grade 5: Death.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=13 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part C: Number of Participants With Grade 3 or 4 (Greater Than [>] 20 Percent [%] of Total) in Laboratory Parameters Based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v5.0) Low lymphocytes	8 Participants	—	—	—	—	—	—	—	—	—
Part C: Number of Participants With Grade 3 or 4 (Greater Than [>] 20 Percent [%] of Total) in Laboratory Parameters Based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v5.0) Low hemoglobin	6 Participants	—	—	—	—	—	—	—	—	—
Part C: Number of Participants With Grade 3 or 4 (Greater Than [>] 20 Percent [%] of Total) in Laboratory Parameters Based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v5.0) Total Bilirubin	7 Participants	—	—	—	—	—	—	—	—	—
Part C: Number of Participants With Grade 3 or 4 (Greater Than [>] 20 Percent [%] of Total) in Laboratory Parameters Based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v5.0) Aspartate Aminotransferase	4 Participants	—	—	—	—	—	—	—	—	—
Part C: Number of Participants With Grade 3 or 4 (Greater Than [>] 20 Percent [%] of Total) in Laboratory Parameters Based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v5.0) Alanine Aminotransferase	3 Participants	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: up to Safety follow-up (Week 31.1)

Population: The SAF included all participants who received at least one dose of study drug.

Vital signs included body temperature, heart rate, systolic and diastolic blood pressure and respiration rate. Number of participants with clinically relevant findings in vital signs were reported. Clinical relevance was decided by Investigator.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=13 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part C: Number of Participants With Clinically Relevant Findings in Vital Signs	0 Participants	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: up to Safety follow-up (Week 31.1)

Population: The SAF included all participants who received at least one dose of study drug.

ECG parameters included PR interval, RR interval, QT interval, QRS duration, QTc intervals (derived using Fridericia's correction method) and heart rate. A 12-lead ECG was recorded with the participant in a supine position after a rest of at least 5 minutes using an ECG machine. Clinical significance was determined by investigator. Number of participants with clinically significant abnormalities in 12-lead ECGs were reported.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=13 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part C: Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECGs)	6 Participants	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Time from first dose of study treatment up to 6.4 years

Population: Full Analysis Set (FAS) included all participants who received at least one dose of study drug.

OR is defined as the confirmed assessment of best overall response of complete response (CR) or partial response (PR). CR is defined as disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=13 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part C: Percentage of Participants With Objective Response (OR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by the Investigator	0.0 percentage of participants Interval 0.0 to 20.6	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours post-dose on Day 1 and Day 8 of Cycle 1 (each cycle is of 21 days)

Population: The Pharmacokinetic Analysis Set (PAS) included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received. Here, "Number Analyzed" signifies those participants who were evaluable for this outcome measure at specified time points.

Cmax was obtained directly from the plasma concentration versus time curve.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=2 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=1 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=2 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=1 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW n=1 Participants Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW n=2 Participants Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW n=4 Participants Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW n=12 Participants Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW n=10 Participants Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW n=7 Participants Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A: Maximum Observed Plasma Concentration (Cmax) of M4344 Cycle 1 Day 1	NA nanogram per milliliter (ng/mL) Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA nanogram per milliliter (ng/mL) Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA nanogram per milliliter (ng/mL) Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA nanogram per milliliter (ng/mL) Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA nanogram per milliliter (ng/mL) Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA nanogram per milliliter (ng/mL) Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	376 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 64.2	516 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 83.6	395 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 73.2	576 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 79.9
Part A: Maximum Observed Plasma Concentration (Cmax) of M4344 Cycle 1 Day 8	NA nanogram per milliliter (ng/mL) Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA nanogram per milliliter (ng/mL) Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA nanogram per milliliter (ng/mL) Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA nanogram per milliliter (ng/mL) Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA nanogram per milliliter (ng/mL) Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA nanogram per milliliter (ng/mL) Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	342 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 136.6	675 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 65.7	328 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 313.1	486 nanogram per milliliter (ng/mL) Geometric Coefficient of Variation 23.8

SECONDARY outcome

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours post-dose on Day 1 and Day 8 of Cycle 1 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received. Here, "Number Analyzed" signifies those participants who were evaluable for this outcome measure at specified time points.

Area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLOQ). AUC0-t was calculated according to the mixed log-linear trapezoidal rule.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=2 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=1 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=2 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=1 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW n=1 Participants Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW n=2 Participants Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW n=4 Participants Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW n=12 Participants Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW n=10 Participants Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW n=7 Participants Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A: Area Under the Plasma Concentration Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of M4344 Cycle 1 Day 1	NA nanogram*hour per milliliter (ng*h/mL) Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA nanogram*hour per milliliter (ng*h/mL) Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA nanogram*hour per milliliter (ng*h/mL) Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA nanogram*hour per milliliter (ng*h/mL) Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA nanogram*hour per milliliter (ng*h/mL) Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA nanogram*hour per milliliter (ng*h/mL) Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	948 nanogram*hour per milliliter (ng*h/mL) Geometric Coefficient of Variation 56.4	1830 nanogram*hour per milliliter (ng*h/mL) Geometric Coefficient of Variation 102.0	1390 nanogram*hour per milliliter (ng*h/mL) Geometric Coefficient of Variation 64.5	2220 nanogram*hour per milliliter (ng*h/mL) Geometric Coefficient of Variation 105.9
Part A: Area Under the Plasma Concentration Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of M4344 Cycle 1 Day 8	NA nanogram*hour per milliliter (ng*h/mL) Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA nanogram*hour per milliliter (ng*h/mL) Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA nanogram*hour per milliliter (ng*h/mL) Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA nanogram*hour per milliliter (ng*h/mL) Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA nanogram*hour per milliliter (ng*h/mL) Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA nanogram*hour per milliliter (ng*h/mL) Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	809 nanogram*hour per milliliter (ng*h/mL) Geometric Coefficient of Variation 96.6	2670 nanogram*hour per milliliter (ng*h/mL) Geometric Coefficient of Variation 91.2	1550 nanogram*hour per milliliter (ng*h/mL) Geometric Coefficient of Variation 295.1	1880 nanogram*hour per milliliter (ng*h/mL) Geometric Coefficient of Variation 74.0

SECONDARY outcome

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours post-dose on Cycle 1 Day 1 (each cycle is of 21 days)

Population: The Pharmacokinetic Analysis Set (PAS) included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received. Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure.

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Lambda z, where Clast pred was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLOQ) and Lambda z was the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=2 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=1 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=2 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=1 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW n=1 Participants Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW n=2 Participants Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW n=4 Participants Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW n=10 Participants Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW n=6 Participants Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW n=3 Participants Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of M4344	NA ng*h/mL Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ng*h/mL Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ng*h/mL Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ng*h/mL Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ng*h/mL Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ng*h/mL Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	971 ng*h/mL Geometric Coefficient of Variation 53.6	1710 ng*h/mL Geometric Coefficient of Variation 92.5	1760 ng*h/mL Geometric Coefficient of Variation 122.3	1540 ng*h/mL Geometric Coefficient of Variation 128.9

SECONDARY outcome

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours post-dose on Day 1 and Day 8 of Cycle 1 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received. Here, "Number Analyzed" signifies those participants who were evaluable for this outcome measure at specified time points.

Tmax was obtained directly from the plasma concentration versus time curve.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=2 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=1 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=2 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=1 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW n=1 Participants Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW n=2 Participants Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW n=4 Participants Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW n=12 Participants Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW n=10 Participants Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW n=7 Participants Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A: Time to Reach Maximum Plasma Concentration (Tmax) of M4344 Cycle 1 Day 1	NA hours Median and Full range were not to be calculated if fewer than 3 participants have reportable parameter values.	NA hours Median and Full range were not to be calculated if fewer than 3 participants have reportable parameter values.	NA hours Median and Full range were not to be calculated if fewer than 3 participants have reportable parameter values.	NA hours Median and Full range were not to be calculated if fewer than 3 participants have reportable parameter values.	NA hours Median and Full range were not to be calculated if fewer than 3 participants have reportable parameter values.	NA hours Median and Full range were not to be calculated if fewer than 3 participants have reportable parameter values.	1.51 hours Interval 0.663 to 2.15	2.00 hours Interval 0.533 to 8.0	2.06 hours Interval 1.5 to 4.0	3.07 hours Interval 1.5 to 4.07
Part A: Time to Reach Maximum Plasma Concentration (Tmax) of M4344 Cycle 1 Day 8	NA hours Median and Full range were not to be calculated if fewer than 3 participants have reportable parameter values.	NA hours Median and Full range were not to be calculated if fewer than 3 participants have reportable parameter values.	NA hours Median and Full range were not to be calculated if fewer than 3 participants have reportable parameter values.	NA hours Median and Full range were not to be calculated if fewer than 3 participants have reportable parameter values.	NA hours Median and Full range were not to be calculated if fewer than 3 participants have reportable parameter values.	NA hours Median and Full range were not to be calculated if fewer than 3 participants have reportable parameter values.	1.22 hours Interval 1.05 to 1.5	2.00 hours Interval 1.57 to 3.95	4.00 hours Interval 1.52 to 8.05	3.95 hours Interval 3.0 to 4.0

SECONDARY outcome

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours post-dose on Day 1 and Day 8 of Cycle 1 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received. Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure and "Number Analyzed" signifies those participants who were evaluable for this outcome measure at specified time points.

Elimination Half Life (T1/2) was defined as the time required for the concentration or amount of drug in the body to be reduced by one-half. T1/2 was calculated by natural log 2 divided by Lambda z. Lambda z was determined from the terminal slope of the log-transformed plasma concentration curve using linear regression method.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=2 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=1 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=2 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=1 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW n=1 Participants Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW n=2 Participants Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW n=4 Participants Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW n=10 Participants Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW n=6 Participants Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW n=3 Participants Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A: Terminal Elimination Half-Life (T1/2) of M4344 Cycle 1 Day 1	NA hours Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA hours Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA hours Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA hours Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA hours Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA hours Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	2.22 hours Geometric Coefficient of Variation 99.0	3.33 hours Geometric Coefficient of Variation 42.3	4.61 hours Geometric Coefficient of Variation 65.2	3.60 hours Geometric Coefficient of Variation 39.9
Part A: Terminal Elimination Half-Life (T1/2) of M4344 Cycle 1 Day 8	NA hours Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA hours Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA hours Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA hours Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA hours Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA hours Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	2.19 hours Geometric Coefficient of Variation 220.1	3.11 hours Geometric Coefficient of Variation 64.2	NA hours Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	—

SECONDARY outcome

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours post-dose on Day 1 and Day 8 of Cycle 1 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received. Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure and "Number Analyzed" signifies those participants who were evaluable for this outcome measure at specified time points.

CL/f was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. CL/f was calculated as Dose/AUC0-inf, where AUC0-inf was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. AUC0-inf was calculated as AUC0-t + Clast pred/Lambda Z, where Clast pred was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration was at or above the lower limit of quantification (LLQ) and Lambda Z was the apparent terminal rate constant determined from the terminal slope of the log-transformed plasma concentration curve.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=2 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=1 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=2 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=1 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW n=1 Participants Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW n=2 Participants Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW n=4 Participants Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW n=10 Participants Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW n=6 Participants Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW n=3 Participants Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A: Apparent Clearance (CL/f) of M4344 Cycle 1 Day 1	NA liter per hour Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA liter per hour Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA liter per hour Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA liter per hour Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA liter per hour Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA liter per hour Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	464 liter per hour Geometric Coefficient of Variation 53.6	409 liter per hour Geometric Coefficient of Variation 92.5	597 liter per hour Geometric Coefficient of Variation 122.3	781 liter per hour Geometric Coefficient of Variation 128.9
Part A: Apparent Clearance (CL/f) of M4344 Cycle 1 Day 8	NA liter per hour Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA liter per hour Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA liter per hour Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA liter per hour Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA liter per hour Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA liter per hour Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	513 liter per hour Geometric Coefficient of Variation 78.2	221 liter per hour Geometric Coefficient of Variation 114.3	NA liter per hour Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	—

SECONDARY outcome

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours post-dose on Day 1 and Day 8 of Cycle 1 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received. Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure and "Number Analyzed" signifies those participants who were evaluable for this outcome measure at specified time points.

Vz/f: the distribution of a study drug between plasma and the rest of the body after oral dosing. For single dose Vz/f = Dose/(AUC0-inf*Lambda Z), where AUC0-inf = (AUC0-t + Clast pred/Lambda Z). Clastpred was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration was at or above the LLOQ and Lambda Z = the apparent terminal rate constant determined from the terminal slope of the log-transformed plasma concentration curve.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=2 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=1 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=2 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=1 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW n=1 Participants Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW n=2 Participants Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW n=4 Participants Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW n=10 Participants Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW n=6 Participants Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW n=3 Participants Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A: Apparent Volume of Distribution During Terminal Phase (Vz/f) of M4344 Cycle 1 Day 8	NA liters Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA liters Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA liters Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA liters Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA liters Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA liters Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	1620 liters Geometric Coefficient of Variation 716.8	993 liters Geometric Coefficient of Variation 59.6	NA liters Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	—
Part A: Apparent Volume of Distribution During Terminal Phase (Vz/f) of M4344 Cycle 1 Day 1	NA liters Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA liters Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA liters Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA liters Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA liters Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA liters Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	1480 liters Geometric Coefficient of Variation 187.9	1960 liters Geometric Coefficient of Variation 116.0	3970 liters Geometric Coefficient of Variation 95.8	4060 liters Geometric Coefficient of Variation 211.6

SECONDARY outcome

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours post-dose on Day 1 and Day 8 of Cycle 1 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received. Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure.

Accumulation ratio of Cmax was calculated as Cmax, after dosing on Day 8 divided by Cmax, after dosing on Day 1 of Cycle 1.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=2 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=1 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=1 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=1 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW n=1 Participants Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW n=2 Participants Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW n=3 Participants Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW n=7 Participants Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW n=6 Participants Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW n=3 Participants Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A: Accumulation Ratio for Maximum Observed Plasma Concentration (Racc [Cmax]) of M4344	NA ratio Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ratio Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ratio Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ratio Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ratio Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ratio Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	0.988 ratio Geometric Coefficient of Variation 37.9	1.19 ratio Geometric Coefficient of Variation 67.5	1.01 ratio Geometric Coefficient of Variation 163.2	1.55 ratio Geometric Coefficient of Variation 17.4

SECONDARY outcome

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours post-dose on Day 1 and Day 8 of Cycle 1 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received. Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure.

Accumulation ratio of AUC0-t was calculated as AUC0-t, after dosing on Day 8 divided by AUC0-t, after dosing on Day 1 of Cycle 1.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=2 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=1 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=1 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=1 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW n=1 Participants Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW n=2 Participants Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW n=3 Participants Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW n=7 Participants Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW n=6 Participants Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW n=3 Participants Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A: Accumulation Ratio for Area Under the Plasma Concentration Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (Racc [AUC0-t]) of M4344	NA ratio Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ratio Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ratio Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ratio Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ratio Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ratio Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	0.955 ratio Geometric Coefficient of Variation 23.7	1.46 ratio Geometric Coefficient of Variation 77.8	1.36 ratio Geometric Coefficient of Variation 163.7	1.89 ratio Geometric Coefficient of Variation 33.6

SECONDARY outcome

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours post-dose on Day 1 and Day 8 of Cycle 1 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received. Here, "Number Analyzed" signifies those participants who were evaluable for this outcome measure at specified time points.

Dose normalized was calculated as Cmax obtained directly from the concentration versus time curve divided by dose. Cmax/dose was measured in nanogram per milliliter per milligram (ng/mL/mg).

Outcome measures

Measure	Part A: M4344 10 mg BIW n=2 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=1 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=2 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=1 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW n=1 Participants Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW n=2 Participants Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW n=4 Participants Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW n=12 Participants Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW n=10 Participants Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW n=7 Participants Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A: Dose Normalized Maximum Observed Plasma Concentration (Cmax/Dose) of M4344 Cycle 1 Day 1	NA ng/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ng/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ng/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ng/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ng/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ng/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	0.835 ng/mL/mg Geometric Coefficient of Variation 64.2	0.738 ng/mL/mg Geometric Coefficient of Variation 83.6	0.376 ng/mL/mg Geometric Coefficient of Variation 73.2	0.480 ng/mL/mg Geometric Coefficient of Variation 79.9
Part A: Dose Normalized Maximum Observed Plasma Concentration (Cmax/Dose) of M4344 Cycle 1 Day 8	NA ng/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ng/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ng/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ng/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ng/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ng/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	0.760 ng/mL/mg Geometric Coefficient of Variation 136.6	0.964 ng/mL/mg Geometric Coefficient of Variation 65.7	0.312 ng/mL/mg Geometric Coefficient of Variation 313.1	0.405 ng/mL/mg Geometric Coefficient of Variation 23.8

SECONDARY outcome

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours post-dose on Day 1 and Day 8 of Cycle 1 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received. Here, "Number Analyzed" signifies those participants who were evaluable for this outcome measure at specified time points.

AUC0-t/Dose was defined as AUC from time of dosing to the time of the last measurable concentration divided by dose. AUC0-t/dose was measured in nanogram*hour per milliliter per milligram (ng*h/mL/mg).

Outcome measures

Measure	Part A: M4344 10 mg BIW n=2 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=1 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=2 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=1 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW n=1 Participants Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW n=2 Participants Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW n=4 Participants Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW n=12 Participants Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW n=10 Participants Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW n=7 Participants Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A: Dose Normalized Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-t/Dose) of M4344 Cycle 1 Day 8	NA ng*h/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ng*h/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ng*h/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ng*h/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ng*h/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ng*h/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	1.80 ng*h/mL/mg Geometric Coefficient of Variation 96.6	3.82 ng*h/mL/mg Geometric Coefficient of Variation 91.2	1.47 ng*h/mL/mg Geometric Coefficient of Variation 295.1	1.57 ng*h/mL/mg Geometric Coefficient of Variation 74.0
Part A: Dose Normalized Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-t/Dose) of M4344 Cycle 1 Day 1	NA ng*h/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ng*h/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ng*h/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ng*h/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ng*h/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ng*h/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	2.11 ng*h/mL/mg Geometric Coefficient of Variation 56.4	2.61 ng*h/mL/mg Geometric Coefficient of Variation 102.0	1.32 ng*h/mL/mg Geometric Coefficient of Variation 64.5	1.85 ng*h/mL/mg Geometric Coefficient of Variation 105.9

SECONDARY outcome

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 8, and 24 hours post-dose on Cycle 1 Day 1 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received. Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure.

AUC0-inf/Dose was defined as AUC extrapolated to infinity divided by dose.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=2 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=1 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=2 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=1 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW n=1 Participants Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW n=2 Participants Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW n=4 Participants Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW n=10 Participants Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW n=6 Participants Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW n=3 Participants Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A: Dose Normalized Area Under the Concentration-Time Curve Over Entire Dosing Time Period From Time Zero Extrapolated to Infinity (AUC0-inf/Dose) of M4344	NA ng*h/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ng*h/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ng*h/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ng*h/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ng*h/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	NA ng*h/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	2.16 ng*h/mL/mg Geometric Coefficient of Variation 53.6	2.45 ng*h/mL/mg Geometric Coefficient of Variation 92.5	1.68 ng*h/mL/mg Geometric Coefficient of Variation 122.3	1.28 ng*h/mL/mg Geometric Coefficient of Variation 128.9

SECONDARY outcome

Timeframe: Time from first dose of study treatment up to 4.3 years

Population: Full analysis set (FAS): all enrolled participants who satisfy all of the following criteria: received at least 1 dose of study drug with the actual amount \> 0 mg; have a baseline scan with a measurable target lesion (sum of diameters of all target lesions \> 0 mm) and have at least 1 disease assessment on treatment with a measurable target lesion (sum of diameters of all target lesions \>= 0 mm); or subjects who have discontinued the study due to either progressive disease or death.

The OR was defined as the confirmed assessment of best overall response (BOR) of partial response (PR),or complete response (CR) according to RECIST v1.1. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in sum of longest diameter (SLD) of all lesions.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=1 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=1 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=1 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=1 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW n=1 Participants Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW n=1 Participants Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW n=3 Participants Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW n=6 Participants Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW n=7 Participants Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW n=4 Participants Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A: Percentage of Participants With Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)	0.0 percentage of participants Interval 0.0 to 95.0	0.0 percentage of participants Interval 0.0 to 95.0	0.0 percentage of participants Interval 0.0 to 95.0	0.0 percentage of participants Interval 0.0 to 95.0	0.0 percentage of participants Interval 0.0 to 95.0	0.0 percentage of participants Interval 0.0 to 95.0	0.0 percentage of participants Interval 0.0 to 63.2	0.0 percentage of participants Interval 0.0 to 39.3	0.0 percentage of participants Interval 0.0 to 34.8	0.0 percentage of participants Interval 0.0 to 52.7

SECONDARY outcome

Timeframe: Time from first dose of study treatment up to 4.3 years

Population: FAS: all enrolled participants who satisfy all of the following criteria: received at least 1 dose of study drug with the actual amount \> 0 mg; have a baseline scan with a measurable target lesion (sum of diameters of all target lesions \> 0 mm) and have at least 1 disease assessment on treatment with a measurable target lesion (sum of diameters of all target lesions \>= 0 mm); or subjects who have discontinued the study due to either progressive disease or death.

SD is defined as neither sufficient increase to qualify for progression disease (PD) nor sufficient shrinkage to qualify for partial response (PR). PR: at least 30 percent (%) reduction from baseline in sum of longest diameter (SLD) of all lesions. PD: at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=1 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=1 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=1 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=1 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW n=1 Participants Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW n=1 Participants Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW n=3 Participants Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW n=6 Participants Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW n=7 Participants Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW n=4 Participants Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A: Number of Participants With Stable Disease (SD) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	2 Participants	2 Participants	1 Participants	1 Participants

SECONDARY outcome

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 8 and 12 hours post-dose on Day 1 and Day 8 of Cycle 1 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received. Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure and "Number Analyzed" signifies those participants who were evaluable at specified time points.

Cmax was obtained directly from the plasma concentration versus time curve.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=6 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=5 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=7 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=7 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A2: Maximum Observed Plasma Concentration (Cmax) of M4344 Cycle 1 Day 8	114 ng/mL Geometric Coefficient of Variation 32.3	244 ng/mL Geometric Coefficient of Variation 59.3	379 ng/mL Geometric Coefficient of Variation 88.9	NA ng/mL Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	—	—	—	—	—	—
Part A2: Maximum Observed Plasma Concentration (Cmax) of M4344 Cycle 1 Day 1	111 ng/mL Geometric Coefficient of Variation 40.3	124 ng/mL Geometric Coefficient of Variation 392.2	517 ng/mL Geometric Coefficient of Variation 78.3	265 ng/mL Geometric Coefficient of Variation 152.7	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 8 and 12 hours post-dose on Cycle 1 Day 1 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received. Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure.

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Lambda z, where Clast pred was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLOQ) and Lambda z was the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=6 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=5 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=6 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=7 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A2: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of M4344	217 ng*h/mL Geometric Coefficient of Variation 44.2	436 ng*h/mL Geometric Coefficient of Variation 127.4	1210 ng*h/mL Geometric Coefficient of Variation 95.0	680 ng*h/mL Geometric Coefficient of Variation 144.1	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 (in BID arms), 24 hours post-dose (in QD arms) on Day 1 and Day 8 of Cycle 1 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received. Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure and "Number Analyzed" signifies those participants who were evaluable for this outcome measure at specified time points.

Area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLOQ). AUC0-t was calculated according to the mixed log-linear trapezoidal rule.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=6 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=5 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=7 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=7 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A2: Area Under the Plasma Concentration Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of M4344 Cycle 1 Day 1	216 ng*h/mL Geometric Coefficient of Variation 43.2	414 ng*h/mL Geometric Coefficient of Variation 142.9	1230 ng*h/mL Geometric Coefficient of Variation 86.1	703 ng*h/mL Geometric Coefficient of Variation 142.7	—	—	—	—	—	—
Part A2: Area Under the Plasma Concentration Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of M4344 Cycle 1 Day 8	236 ng*h/mL Geometric Coefficient of Variation 55.4	627 ng*h/mL Geometric Coefficient of Variation 58.9	829 ng*h/mL Geometric Coefficient of Variation 101.4	NA ng*h/mL Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 8 and 12 hours post-dose on Day 1 and Day 8 of Cycle 1 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received. Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure and "Number Analyzed" signifies those participants who were evaluable for this outcome measure at specified time points.

Tmax was obtained directly from the plasma concentration versus time curve.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=6 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=5 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=7 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=7 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A2: Time to Reach Maximum Plasma Concentration (Tmax) of M4344 Cycle 1 Day 8	1.03 hours Interval 1.0 to 1.43	1.28 hours Interval 0.5 to 2.0	1.50 hours Interval 0.5 to 1.95	NA hours Median and Full range were not to be calculated if fewer than 3 participants have reportable parameter values.	—	—	—	—	—	—
Part A2: Time to Reach Maximum Plasma Concentration (Tmax) of M4344 Cycle 1 Day 1	1.45 hours Interval 0.517 to 2.0	1.62 hours Interval 0.467 to 2.07	1.50 hours Interval 0.5 to 2.0	1.10 hours Interval 0.683 to 3.02	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 8 and 12 hours post-dose on Day 1 and Day 8 of Cycle 1 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received. Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure and "Number Analyzed" signifies those participants who were evaluable for this outcome measure at specified time points.

Elimination Half Life (T1/2) was defined as the time required for the concentration or amount of drug in the body to be reduced by one-half. T1/2 was calculated by natural log 2 divided by Lambda z. Lambda z was determined from the terminal slope of the log-transformed plasma concentration curve using linear regression method.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=6 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=5 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=7 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=7 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A2: Terminal Elimination Half-Life (T1/2) of M4344 Cycle 1 Day 1	1.32 hours Geometric Coefficient of Variation 27.1	2.47 hours Geometric Coefficient of Variation 165.9	1.74 hours Geometric Coefficient of Variation 58.8	2.37 hours Geometric Coefficient of Variation 60.9	—	—	—	—	—	—
Part A2: Terminal Elimination Half-Life (T1/2) of M4344 Cycle 1 Day 8	1.36 hours Geometric Coefficient of Variation 58.7	1.31 hours Geometric Coefficient of Variation 28.9	1.31 hours Geometric Coefficient of Variation 18.7	NA hours Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 8 and 12 hours post-dose on Day 1 and Day 8 of Cycle 1 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received. Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure and "Number Analyzed" signifies those participants who were evaluable for this outcome measure at specified time points.

CL/f was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. CL/f was calculated as Dose/AUC0-inf, where AUC0-inf was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. AUC0-inf was calculated as AUC0-t + Clast pred/Lambda Z, where Clast pred was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration was at or above the lower limit of quantification (LLQ) and Lambda Z was the apparent terminal rate constant determined from the terminal slope of the log-transformed plasma concentration curve.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=6 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=5 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=7 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=7 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A2: Apparent Clearance (CL/f) of M4344 Cycle 1 Day 1	461 liter per hour Geometric Coefficient of Variation 44.2	344 liter per hour Geometric Coefficient of Variation 127.4	207 liter per hour Geometric Coefficient of Variation 95.0	515 liter per hour Geometric Coefficient of Variation 144.1	—	—	—	—	—	—
Part A2: Apparent Clearance (CL/f) of M4344 Cycle 1 Day 8	424 liter per hour Geometric Coefficient of Variation 55.4	239 liter per hour Geometric Coefficient of Variation 58.9	302 liter per hour Geometric Coefficient of Variation 101.4	NA liter per hour Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 8 and 12 hours post-dose on Cycle 1 Day 1 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received. Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure.

Vz/f: the distribution of a study drug between plasma and the rest of the body after oral dosing. For single dose Vz/f = Dose/(AUC0-inf*Lambda Z), where AUC0-inf = (AUC0-t + Clast pred/Lambda Z). Clastpred was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration was at or above the LLOQ and Lambda Z = the apparent terminal rate constant determined from the terminal slope of the log-transformed plasma concentration curve.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=6 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=5 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=6 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=7 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A2: Apparent Volume of Distribution During Terminal Phase (Vz/f) of M4344	876 liters Geometric Coefficient of Variation 36.3	1220 liters Geometric Coefficient of Variation 661.7	519 liters Geometric Coefficient of Variation 191.1	1760 liters Geometric Coefficient of Variation 214.7	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 8 and 12 hours post-dose on Day 1 and Day 8 of Cycle 1 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received. Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure.

Accumulation ratio of Cmax was calculated as Cmax, after dosing on Day 8 divided by Cmax, after dosing on Day 1 of Cycle 1.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=3 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=4 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=7 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=2 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A2: Accumulation Ratio for Maximum Observed Plasma Concentration (Racc [Cmax]) of M4344	1.08 ratio Geometric Coefficient of Variation 47.5	2.26 ratio Geometric Coefficient of Variation 245.2	0.733 ratio Geometric Coefficient of Variation 92.1	NA ratio Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 (in BID arms), 24 hours post-dose (in QD arms) on Day 1 and Day 8 of Cycle 1 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received. Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure.

Accumulation ratio of AUC0-t was calculated as AUC0-t, after dosing on Day 8 divided by AUC0-t, after dosing on Day 1 of Cycle 1.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=3 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=4 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=7 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=2 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A2: Accumulation Ratio for Area Under the Plasma Concentration Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (Racc [AUC0-t]) of M4344	1.00 ratio Geometric Coefficient of Variation 55.3	1.42 ratio Geometric Coefficient of Variation 142.4	0.672 ratio Geometric Coefficient of Variation 90.7	NA ratio Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 8 and 12 hours post-dose on Day 1 and Day 8 of Cycle 1 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received. Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure.

Accumulation ratio of AUC was calculated as AUC, after dosing on Day 8 divided by AUC, after dosing on Day 1 of Cycle 1.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=3 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=4 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=7 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=2 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A2: Accumulation Ratio for Area Under the Plasma Concentration Time Curve (Racc [AUC]) of M4344	0.997 ratio Geometric Coefficient of Variation 55.7	1.32 ratio Geometric Coefficient of Variation 133.5	0.676 ratio Geometric Coefficient of Variation 88.4	NA ratio Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 8 and 12 hours post-dose on Day 1 and Day 8 of Cycle 1 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received. Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure and "Number Analyzed" signifies those participants who were evaluable for this outcome measure at specified time points.

Dose normalized was calculated as Cmax obtained directly from the concentration versus time curve divided by dose. Cmax/dose was measured in nanogram per milliliter per milligram (ng/mL/mg).

Outcome measures

Measure	Part A: M4344 10 mg BIW n=6 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=5 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=7 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=7 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A2: Dose Normalized Maximum Observed Plasma Concentration (Cmax/Dose) of M4344 Cycle 1 Day 1	1.11 ng/mL/mg Geometric Coefficient of Variation 40.3	0.829 ng/mL/mg Geometric Coefficient of Variation 392.2	2.07 ng/mL/mg Geometric Coefficient of Variation 78.3	0.758 ng/mL/mg Geometric Coefficient of Variation 152.7	—	—	—	—	—	—
Part A2: Dose Normalized Maximum Observed Plasma Concentration (Cmax/Dose) of M4344 Cycle 1 Day 8	1.14 ng/mL/mg Geometric Coefficient of Variation 32.3	1.63 ng/mL/mg Geometric Coefficient of Variation 59.3	1.52 ng/mL/mg Geometric Coefficient of Variation 88.9	NA ng/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 8 and 12 hours post-dose on Cycle 1 Day 1 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received. Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure.

AUC0-inf/Dose was defined as AUC extrapolated to infinity divided by dose. AUC0-inf/Dose was measured in nanogram*hour per milliliter per milligram (ng*h/mL/mg).

Outcome measures

Measure	Part A: M4344 10 mg BIW n=6 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=5 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=6 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=7 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A2: Dose Normalized Area Under the Concentration-Time Curve Over Entire Dosing Time Period From Time Zero Extrapolated to Infinity (AUC0-inf/Dose) of M4344	2.17 ng*h/mL/mg Geometric Coefficient of Variation 44.2	2.91 ng*h/mL/mg Geometric Coefficient of Variation 127.4	4.84 ng*h/mL/mg Geometric Coefficient of Variation 95.0	1.94 ng*h/mL/mg Geometric Coefficient of Variation 144.1	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 (in BID arms), 24 hours post-dose (in QD arms) on Day 1 and Day 8 of Cycle 1 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received. Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure and "Number Analyzed" signifies those participants who were evaluable for this outcome measure at specified time points.

AUC0-t/Dose was defined as AUC from time of dosing to the time of the last measurable concentration divided by dose.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=6 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=5 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=7 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=7 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A2: Dose Normalized Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-t/Dose) of M4344 Cycle 1 Day 1	2.16 ng*h/mL/mg Geometric Coefficient of Variation 43.2	2.76 ng*h/mL/mg Geometric Coefficient of Variation 142.9	4.93 ng*h/mL/mg Geometric Coefficient of Variation 86.1	2.01 ng*h/mL/mg Geometric Coefficient of Variation 142.7	—	—	—	—	—	—
Part A2: Dose Normalized Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-t/Dose) of M4344 Cycle 1 Day 8	2.36 ng*h/mL/mg Geometric Coefficient of Variation 55.4	4.18 ng*h/mL/mg Geometric Coefficient of Variation 58.9	3.32 ng*h/mL/mg Geometric Coefficient of Variation 101.4	NA ng*h/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Time from first dose of study treatment up to 6.2 years

Population: FAS is defined as all enrolled participants who received at least 1 dose of study drug, have a baseline scan, and received at least one disease assessment while on treatment.

SD is defined as neither sufficient increase to qualify for progression disease (PD) nor sufficient shrinkage to qualify for partial response (PR). PR: at least 30 percent (%) reduction from baseline in sum of longest diameter (SLD) of all lesions. PD: at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=7 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=4 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=7 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=5 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A2: Number of Participants With Stable Disease (SD) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)	1 Participants	1 Participants	4 Participants	2 Participants	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Time from first dose of study treatment up to 6.2 years

Population: FAS is defined as all enrolled participants who received at least 1 dose of study drug, have a baseline scan, and received at least one disease assessment while on treatment.

The OR was defined as the confirmed assessment of best overall response (BOR) of partial response (PR),or complete response (CR) according to RECIST v1.1. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in sum of longest diameter (SLD) of all lesions.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=7 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=4 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=7 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=5 Participants Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part A2: Percentage of Participants With Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)	0.0 percentage of participants Interval 0.0 to 34.8	0.0 percentage of participants Interval 0.0 to 52.7	0.0 percentage of participants Interval 0.0 to 34.8	0.0 percentage of participants Interval 0.0 to 45.1	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours post-dose on Cycle 1 Day 2 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received.

Cmax was obtained directly from the plasma concentration versus time curve.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=3 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=7 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=6 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part B1: Maximum Observed Plasma Concentration (Cmax) of M4344	309 ng/mL Geometric Coefficient of Variation 78.1	114 ng/mL Geometric Coefficient of Variation 191.6	367 ng/mL Geometric Coefficient of Variation 89.8	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours post-dose on Cycle 1 Day 2 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received.

Area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLOQ). AUC0-t was calculated according to the mixed log-linear trapezoidal rule.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=3 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=7 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=6 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part B1: Area Under the Plasma Concentration Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of M4344	392 ng*h/mL Geometric Coefficient of Variation 101.8	268 ng*h/mL Geometric Coefficient of Variation 179.6	1450 ng*h/mL Geometric Coefficient of Variation 115.6	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours post-dose on Cycle 1 Day 2 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received. Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure.

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Lambda z, where Clast pred was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLOQ) and Lambda z was the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=2 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=4 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=3 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part B1: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of M4344	NA ng*h/mL Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	368 ng*h/mL Geometric Coefficient of Variation 147.3	2570 ng*h/mL Geometric Coefficient of Variation 124.3	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours post-dose on Cycle 1 Day 2 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received.

Tmax was obtained directly from the plasma concentration versus time curve.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=3 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=7 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=6 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part B1:Time to Reach Maximum Plasma Concentration (Tmax) of M4344	1.52 hours Interval 0.9 to 2.0	1.50 hours Interval 0.5 to 8.02	1.96 hours Interval 1.0 to 3.0	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours post-dose on Cycle 1 Day 2 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received. Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure.

Elimination Half Life (T1/2) was defined as the time required for the concentration or amount of drug in the body to be reduced by one-half. T1/2 was calculated by natural log 2 divided by Lambda z. Lambda z was determined from the terminal slope of the log-transformed plasma concentration curve using linear regression method.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=2 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=4 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=3 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part B1: Terminal Elimination Half-Life (T1/2) of M4344	NA hours Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	1.03 hours Geometric Coefficient of Variation 23.6	3.77 hours Geometric Coefficient of Variation 59.1	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours post-dose on Cycle 1 Day 2 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received. Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure.

CL/f was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. CL/f was calculated as Dose/AUC0-inf, where AUC0-inf was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. AUC0-inf was calculated as AUC0-t + Clast pred/Lambda Z, where Clast pred was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration was at or above the lower limit of quantification (LLQ) and Lambda Z was the apparent terminal rate constant determined from the terminal slope of the log-transformed plasma concentration curve.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=2 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=4 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=3 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part B1: Apparent Clearance (CL/f) of M4344	NA liter per hour Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	1090 liter per hour Geometric Coefficient of Variation 147.3	194 liter per hour Geometric Coefficient of Variation 124.3	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours post-dose on Cycle 1 Day 2 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received. Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure.

Vz/f: the distribution of a study drug between plasma and the rest of the body after oral dosing. For single dose Vz/f = Dose/(AUC0-inf*Lambda Z), where AUC0-inf = (AUC0-t + Clast pred/Lambda Z). Clastpred was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration was at or above the LLOQ and Lambda Z = the apparent terminal rate constant determined from the terminal slope of the log-transformed plasma concentration curve.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=2 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=4 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=3 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part B1: Apparent Volume of Distribution During Terminal Phase (Vz/f) of M4344	NA liters Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	1620 liters Geometric Coefficient of Variation 155.5	1060 liters Geometric Coefficient of Variation 45.1	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours post-dose on Cycle 1 Day 2 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received.

Dose normalized was calculated as Cmax obtained directly from the concentration versus time curve divided by dose.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=3 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=7 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=6 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part B1: Dose Normalized Maximum Observed Plasma Concentration (Cmax/Dose) of M4344	0.884 ng/mL/mg Geometric Coefficient of Variation 78.1	0.286 ng/mL/mg Geometric Coefficient of Variation 191.6	0.735 ng/mL/mg Geometric Coefficient of Variation 89.8	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours post-dose on Cycle 1 Day 2 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received.

AUC0-t/Dose was defined as AUC from time of dosing to the time of the last measurable concentration divided by dose.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=3 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=7 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=6 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part B1: Dose Normalized Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-t/Dose) of M4344	1.12 ng*h/mL/mg Geometric Coefficient of Variation 101.8	0.669 ng*h/mL/mg Geometric Coefficient of Variation 179.6	2.90 ng*h/mL/mg Geometric Coefficient of Variation 115.6	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hours post-dose on Cycle 1 Day 2 (each cycle is of 21 days)

Population: The PAS included all enrolled participants who received at least one dose of M4344 with the actual amount \> 0 mg and provide at least one measurable post-dose concentration. Participants were analyzed according to the actual treatment they received. Here, "Overall Number of Participants Analyzed" signifies those participants who were evaluable for this outcome measure.

AUC0-inf/Dose was defined as AUC extrapolated to infinity divided by dose.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=2 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=4 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=3 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part B1: Dose Normalized Area Under the Concentration-Time Curve Over Entire Dosing Time Period From Time Zero Extrapolated to Infinity (AUC0-inf/Dose) of M4344	NA ng*h/mL/mg Geometric Coefficient of Variation NA Geometric Mean and Geometric Coefficient of Variation were not to be calculated if fewer than 3 participants have reportable parameter values.	0.920 ng*h/mL/mg Geometric Coefficient of Variation 147.3	5.15 ng*h/mL/mg Geometric Coefficient of Variation 124.3	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Time from first dose of study treatment up to 5.2 years

Population: FAS is defined as all enrolled participants who received at least 1 dose of study treatment, have a baseline scan with a measurable target lesion, and at least one on-treatment disease assessment or have discontinued the study due to either progressive disease or death.

The OR was defined as the confirmed assessment of best overall response (BOR) of partial response (PR),or complete response (CR) according to RECIST v1.1. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in sum of longest diameter (SLD) of all lesions.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=3 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=7 Participants Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=6 Participants Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part B1: Percentage of Participants With Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)	0.0 percentage of participants Interval 0.0 to 63.2	14.3 percentage of participants Interval 0.7 to 52.1	0.0 percentage of participants Interval 0.0 to 39.3	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Time from first dose of study treatment up to 6.4 years

Population: FAS included all participants who received at least one dose of study drug.

Confirmed BOR is defined as best response of any of complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) recorded from the treatment start date until documented disease progression. CR: Disappearance of all evidence of target/non-target lesions. PR: At least 30%reduction from baseline in sum of longest diameter (SLD) of all lesions. SD: Neither sufficient increase to qualify for PD nor sufficient shrinkage to qualify for PR. PD: at least a 20% increase in SLD, taking as reference smallest SLD recorded from baseline/appearance of 1or more new lesions and unequivocal progression of non-target lesions.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=13 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part C: Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 Complete response (CR)	0 Participants	—	—	—	—	—	—	—	—	—
Part C: Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 Partial response (PR)	0 Participants	—	—	—	—	—	—	—	—	—
Part C: Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 Stable disease (SD)	3 Participants	—	—	—	—	—	—	—	—	—
Part C: Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 Progressive disease (PD)	8 Participants	—	—	—	—	—	—	—	—	—
Part C: Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 Non-CR/Non-PD	0 Participants	—	—	—	—	—	—	—	—	—
Part C: Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 Non-evaluable	2 Participants	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Time from first dose of study treatment up to 6.4 years

Population: FAS included all participants who received at least one dose of study drug.

PFS is defined as the time from start of study treatment to progression disease (PD) or death. PD: at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. PFS was measured using Kaplan-Meier (KM) estimates.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=13 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part C: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 as Assessed by Investigator	1.6 months Interval 0.8 to 2.1	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Time from first documentation of objective response, assessed up to 6.4 years

Population: As per planned analysis, DoR was not analyzed due to the small number of participants and the low likelihood that any participant would experience an objective response.

DOR was defined for participants with confirmed response, as the time from first documentation of objective response (Complete Response [CR] or Partial Response [PR]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the SLD of all lesions. PD: At least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Time from first dose of study treatment up to 6.4 years

Population: FAS included all participants who received at least one dose of study drug. The summarized data was not available for these arms therefore individual data was presented. Here, "Overall Number of Participants" signifies those participants who were evaluable for this outcome measure and "number analyzed" = specific participants evaluated in the arm.

OS was defined as the time from treatment start to the date of death due to any cause. The participants who were still alive at the time of data analysis or who were lost to follow-up OS time was censored at the last recorded date. OS was measured using Kaplan-Meier (KM) estimates.

Outcome measures

Measure	Part A: M4344 10 mg BIW n=6 Participants Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Part C: Overall Survival (OS) Participant 1	1.91 months	—	—	—	—	—	—	—	—	—
Part C: Overall Survival (OS) Participant 2	0.79 months	—	—	—	—	—	—	—	—	—
Part C: Overall Survival (OS) Participant 3	1.61 months	—	—	—	—	—	—	—	—	—
Part C: Overall Survival (OS) Participant 4	3.98 months	—	—	—	—	—	—	—	—	—
Part C: Overall Survival (OS) Participant 5	2.53 months	—	—	—	—	—	—	—	—	—
Part C: Overall Survival (OS) Participant 6	2.63 months	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose up to 2 hours post-dose on Cycle 1 Day 1; Pre-dose up to 1 hours post-dose on Cycle 1 Day 8 and Cycle 1 Day 15 (each cycle is of 21 days)

Population: As per changes in planned analysis, the outcome measures related to pharmacokinetic parameters were not assessed for Part C.

Cmax was obtained directly from the plasma concentration versus time curve.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Pre-dose up to 2 hours post-dose on Cycle 1 Day 1; Pre-dose up to 1 hours post-dose on Cycle 1 Day 8 and Cycle 1 Day 15 (each cycle is of 21 days)

Population: As per changes in planned analysis, the outcome measures related to pharmacokinetic parameters were not assessed for Part C.

Area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLOQ). AUC0-t was calculated according to the mixed log-linear trapezoidal rule.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Pre-dose up to 2 hours post-dose on Cycle 1 Day 1; Pre-dose up to 1 hours post-dose on Cycle 1 Day 8 and Cycle 1 Day 15 (each cycle is of 21 days)

Population: As per changes in planned analysis, the outcome measures related to pharmacokinetic parameters were not assessed for Part C.

Tmax was obtained directly from the plasma concentration versus time curve.

Outcome measures

Outcome data not reported

Adverse Events

Part A: M4344 10 mg BIW

Serious events: 1 serious events

Other events: 2 other events

Deaths: 0 deaths

Part A: M4344 20 mg BIW

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Part A: M4344 40 mg BIW

Serious events: 1 serious events

Other events: 1 other events

Deaths: 1 deaths

Part A: M4344 80 mg BIW

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Part A: M4344 160 mg BIW

Serious events: 1 serious events

Other events: 1 other events

Deaths: 1 deaths

Part A: M4344 300 mg BIW

Serious events: 0 serious events

Other events: 2 other events

Deaths: 1 deaths

Part A: M4344 450 mg BIW

Serious events: 2 serious events

Other events: 4 other events

Deaths: 1 deaths

Part A: M4344 700 mg BIW

Serious events: 6 serious events

Other events: 12 other events

Deaths: 8 deaths

Part A: M4344 1050 mg BIW

Serious events: 6 serious events

Other events: 10 other events

Deaths: 3 deaths

Part A: M4344 1200 mg BIW

Serious events: 4 serious events

Other events: 7 other events

Deaths: 1 deaths

Part A2: M4344 100 mg BID

Serious events: 5 serious events

Other events: 7 other events

Deaths: 5 deaths

Part A2: M4344 150 mg QD

Serious events: 1 serious events

Other events: 5 other events

Deaths: 3 deaths

Part A2: M4344 250 mg QD

Serious events: 2 serious events

Other events: 7 other events

Deaths: 2 deaths

Part A2: M4344 350 mg QD

Serious events: 5 serious events

Other events: 7 other events

Deaths: 3 deaths

Part B1: M4344 350 mg + Carboplatin

Serious events: 1 serious events

Other events: 3 other events

Deaths: 1 deaths

Part B1: M4344 400 mg + Carboplatin

Serious events: 4 serious events

Other events: 7 other events

Deaths: 4 deaths

Part B1: M4344 500 mg + Carboplatin

Serious events: 3 serious events

Other events: 6 other events

Deaths: 2 deaths

Part C: M4344 250 mg QD

Serious events: 7 serious events

Other events: 13 other events

Deaths: 6 deaths

Serious adverse events

Measure	Part A: M4344 10 mg BIW n=2 participants at risk Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=1 participants at risk Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=2 participants at risk Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=1 participants at risk Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW n=1 participants at risk Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW n=2 participants at risk Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW n=4 participants at risk Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW n=12 participants at risk Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW n=10 participants at risk Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW n=7 participants at risk Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A2: M4344 100 mg BID n=7 participants at risk Participants received M4344 at a dose of 100 mg orally twice daily (BID) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A2: M4344 150 mg QD n=5 participants at risk Participants received M4344 at a dose of 150 mg orally once daily (QD) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A2: M4344 250 mg QD n=7 participants at risk Participants received M4344 at a dose of 250 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A2: M4344 350 mg QD n=7 participants at risk Participants received M4344 at a dose of 350 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part B1: M4344 350 mg + Carboplatin n=3 participants at risk Participants received M4344 at a dose of 350 mg orally on Day 2 and Day 9 in combination with intravenous infusion of Carboplatin at a dose of Area under the concentration versus time curve 5 (AUC5) on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part B1: M4344 400 mg + Carboplatin n=7 participants at risk Participants received M4344 at a dose of 400 mg orally on Day 2 and Day 9 in combination with intravenous infusion of Carboplatin at a dose of AUC5 on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part B1: M4344 500 mg + Carboplatin n=6 participants at risk Participants received M4344 at a dose of 500 mg orally on Day 2 and Day 9 in combination with intravenous infusion of Carboplatin at a dose of AUC5 on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part C: M4344 250 mg QD n=13 participants at risk Participants received M4344 at a dose of 250 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Gastrointestinal disorders Abdominal pain	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Gastrointestinal disorders Nausea	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	33.3% 1/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Gastrointestinal disorders Upper gastrointestinal haemorrhage	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	25.0% 1/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Gastrointestinal disorders Vomiting	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	33.3% 1/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
General disorders Disease progression	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	15.4% 2/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
General disorders Pyrexia	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	28.6% 2/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	28.6% 2/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Hepatobiliary disorders Hyperbilirubinaemia	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Immune system disorders Hypersensitivity	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	25.0% 1/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Infections and infestations Upper respiratory tract infection	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	100.0% 1/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Infections and infestations Urosepsis	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Injury, poisoning and procedural complications Fall	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Investigations Alanine aminotransferase increased	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Investigations Aspartate aminotransferase increased	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Investigations Blood bilirubin increased	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	57.1% 4/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colorectal cancer metastatic	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour pain	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Nervous system disorders Cauda equina syndrome	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Renal and urinary disorders Acute kidney injury	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Respiratory, thoracic and mediastinal disorders Pneumonia aspiration	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Gastrointestinal disorders Diarrhoea	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	28.6% 2/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Gastrointestinal disorders Pancreatitis	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Gastrointestinal disorders Small intestinal obstruction	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
General disorders Fatigue	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
General disorders Malaise	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Infections and infestations Biliary sepsis	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	20.0% 1/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Infections and infestations Pneumonia	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Infections and infestations Sepsis	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Investigations Transaminases increased	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Metabolism and nutrition disorders Decreased appetite	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Metabolism and nutrition disorders Dehydration	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Musculoskeletal and connective tissue disorders Flank pain	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Nervous system disorders Seizure	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Nervous system disorders Somnolence	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Blood and lymphatic system disorders Febrile neutropenia	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	16.7% 1/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Blood and lymphatic system disorders Neutropenia	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	33.3% 2/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Gastrointestinal disorders Abdominal distension	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Gastrointestinal disorders Gastrointestinal inflammation	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	16.7% 1/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
General disorders Death	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
General disorders Euthanasia	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	16.7% 1/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Immune system disorders Anaphylactic reaction	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Nervous system disorders Syncope	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Blood and lymphatic system disorders Anaemia	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Gastrointestinal disorders Intestinal obstruction	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Hepatobiliary disorders Biliary obstruction	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Hepatobiliary disorders Hepatic failure	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Infections and infestations Streptococcal infection	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.

Other adverse events

Measure	Part A: M4344 10 mg BIW n=2 participants at risk Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 20 mg BIW n=1 participants at risk Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 40 mg BIW n=2 participants at risk Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 80 mg BIW n=1 participants at risk Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 160 mg BIW n=1 participants at risk Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 300 mg BIW n=2 participants at risk Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 450 mg BIW n=4 participants at risk Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 700 mg BIW n=12 participants at risk Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1050 mg BIW n=10 participants at risk Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A: M4344 1200 mg BIW n=7 participants at risk Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A2: M4344 100 mg BID n=7 participants at risk Participants received M4344 at a dose of 100 mg orally twice daily (BID) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A2: M4344 150 mg QD n=5 participants at risk Participants received M4344 at a dose of 150 mg orally once daily (QD) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A2: M4344 250 mg QD n=7 participants at risk Participants received M4344 at a dose of 250 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part A2: M4344 350 mg QD n=7 participants at risk Participants received M4344 at a dose of 350 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part B1: M4344 350 mg + Carboplatin n=3 participants at risk Participants received M4344 at a dose of 350 mg orally on Day 2 and Day 9 in combination with intravenous infusion of Carboplatin at a dose of Area under the concentration versus time curve 5 (AUC5) on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part B1: M4344 400 mg + Carboplatin n=7 participants at risk Participants received M4344 at a dose of 400 mg orally on Day 2 and Day 9 in combination with intravenous infusion of Carboplatin at a dose of AUC5 on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part B1: M4344 500 mg + Carboplatin n=6 participants at risk Participants received M4344 at a dose of 500 mg orally on Day 2 and Day 9 in combination with intravenous infusion of Carboplatin at a dose of AUC5 on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.	Part C: M4344 250 mg QD n=13 participants at risk Participants received M4344 at a dose of 250 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Psychiatric disorders Insomnia	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Metabolism and nutrition disorders Hypoalbuminaemia	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Investigations Platelet count decreased	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	16.7% 1/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Investigations White blood cell count decreased	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	16.7% 1/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Investigations White blood cell count increased	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	16.7% 1/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Investigations Haemoglobin decreased	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Investigations Neutrophil count increased	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Metabolism and nutrition disorders Decreased appetite	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	100.0% 1/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	100.0% 1/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	50.0% 2/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	42.9% 3/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	66.7% 2/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	16.7% 1/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	15.4% 2/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Metabolism and nutrition disorders Dehydration	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	28.6% 2/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	20.0% 1/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	28.6% 2/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Metabolism and nutrition disorders Hypocalcaemia	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	100.0% 1/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	33.3% 2/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Metabolism and nutrition disorders Hypomagnesaemia	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	42.9% 3/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	16.7% 1/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Metabolism and nutrition disorders Hypophosphataemia	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	100.0% 1/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	28.6% 2/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	25.0% 1/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	33.3% 1/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Musculoskeletal and connective tissue disorders Bone pain	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Musculoskeletal and connective tissue disorders Flank pain	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Musculoskeletal and connective tissue disorders Groin pain	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	100.0% 1/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	33.3% 1/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Musculoskeletal and connective tissue disorders Myalgia	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	100.0% 1/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	28.6% 2/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	16.7% 1/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Musculoskeletal and connective tissue disorders Pain in jaw	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	16.7% 1/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Musculoskeletal and connective tissue disorders Limb discomfort	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Musculoskeletal and connective tissue disorders Muscular weakness	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour obstruction	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour pain	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Nervous system disorders Disturbance in attention	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Nervous system disorders Dizziness	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	100.0% 1/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Nervous system disorders Headache	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	100.0% 1/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	50.0% 2/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	28.6% 2/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	33.3% 1/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	16.7% 1/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Nervous system disorders Peripheral sensory neuropathy	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	25.0% 1/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Nervous system disorders Sinus headache	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	100.0% 1/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Nervous system disorders Memory impairment	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	20.0% 1/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Nervous system disorders Ophthalmic migraine	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Nervous system disorders Neuropathy peripheral	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Psychiatric disorders Anxiety	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Psychiatric disorders Depression	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Renal and urinary disorders Acute kidney injury	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Renal and urinary disorders Chromaturia	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Renal and urinary disorders Chronic kidney disease	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Renal and urinary disorders Dysuria	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Renal and urinary disorders Haematuria	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Renal and urinary disorders Pollakiuria	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Renal and urinary disorders Urinary incontinence	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Renal and urinary disorders Hydronephrosis	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	100.0% 1/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	25.0% 1/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	28.6% 2/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	25.0% 1/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	16.7% 2/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	57.1% 4/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	33.3% 1/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	16.7% 1/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Respiratory, thoracic and mediastinal disorders Productive cough	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	33.3% 1/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Reproductive system and breast disorders Pelvic pain	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Reproductive system and breast disorders Vaginal haemorrhage	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Reproductive system and breast disorders Breast pain	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Skin and subcutaneous tissue disorders Angioedema	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	25.0% 1/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Skin and subcutaneous tissue disorders Dermatitis acneiform	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Skin and subcutaneous tissue disorders Eczema	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	25.0% 1/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Skin and subcutaneous tissue disorders Hyperhidrosis	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Skin and subcutaneous tissue disorders Rash pruritic	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Skin and subcutaneous tissue disorders Night sweats	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Skin and subcutaneous tissue disorders Rash	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	20.0% 1/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	28.6% 2/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Skin and subcutaneous tissue disorders Skin discolouration	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Skin and subcutaneous tissue disorders Erythema	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Skin and subcutaneous tissue disorders Skin burning sensation	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Surgical and medical procedures Tooth extraction	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Vascular disorders Hot flush	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	100.0% 1/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Vascular disorders Hypotension	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Vascular disorders Peripheral coldness	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	25.0% 1/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Vascular disorders Vena cava thrombosis	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Vascular disorders Hypertension	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Gastrointestinal disorders Abdominal discomfort	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	16.7% 1/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Blood and lymphatic system disorders Anaemia	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	25.0% 1/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	40.0% 2/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	57.1% 4/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	28.6% 2/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	33.3% 1/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	57.1% 4/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	50.0% 3/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	53.8% 7/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Blood and lymphatic system disorders Lymphadenopathy	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	100.0% 1/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Blood and lymphatic system disorders Neutropenia	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	66.7% 2/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	28.6% 2/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	50.0% 3/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Cardiac disorders Atrial fibrillation	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Ear and labyrinth disorders Vertigo	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	100.0% 1/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Eye disorders Ocular hyperaemia	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	100.0% 1/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Gastrointestinal disorders Abdominal distension	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	100.0% 1/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Gastrointestinal disorders Abdominal pain	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	25.0% 1/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	30.0% 3/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	28.6% 2/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Gastrointestinal disorders Abdominal pain lower	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Gastrointestinal disorders Abdominal pain upper	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Gastrointestinal disorders Constipation	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	100.0% 2/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	75.0% 3/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	57.1% 4/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	28.6% 2/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	20.0% 1/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	28.6% 2/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	28.6% 2/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	16.7% 1/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	15.4% 2/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Gastrointestinal disorders Diarrhoea	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	25.0% 1/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	25.0% 3/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	28.6% 2/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	40.0% 2/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	28.6% 2/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	16.7% 1/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	15.4% 2/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Gastrointestinal disorders Dry mouth	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Gastrointestinal disorders Dyspepsia	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	16.7% 2/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Gastrointestinal disorders Flatulence	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	25.0% 1/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Gastrointestinal disorders Gastrooesophageal reflux disease	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	33.3% 1/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Gastrointestinal disorders Nausea	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	100.0% 1/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	100.0% 1/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	100.0% 1/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	100.0% 2/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	50.0% 2/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	66.7% 8/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	60.0% 6/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	71.4% 5/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	42.9% 3/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	40.0% 2/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	57.1% 4/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	28.6% 2/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	66.7% 2/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	28.6% 2/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	50.0% 3/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	46.2% 6/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Gastrointestinal disorders Post-tussive vomiting	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Gastrointestinal disorders Rectal haemorrhage	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Gastrointestinal disorders Stomatitis	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Gastrointestinal disorders Vomiting	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	100.0% 1/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	25.0% 1/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	58.3% 7/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	40.0% 4/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	57.1% 4/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	71.4% 5/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	42.9% 3/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	33.3% 1/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	16.7% 1/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	61.5% 8/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	66.7% 2/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	57.1% 4/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	66.7% 4/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Cardiac disorders Palpitations	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Eye disorders Dry eye	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Eye disorders Vision blurred	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	20.0% 1/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Eye disorders Conjunctival haemorrhage	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Eye disorders Retinal haemorrhage	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Gastrointestinal disorders Duodenal obstruction	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Gastrointestinal disorders Eructation	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Gastrointestinal disorders Gastrointestinal haemorrhage	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Gastrointestinal disorders Mouth ulceration	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	16.7% 1/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
General disorders Asthenia	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	100.0% 1/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
General disorders Chills	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	16.7% 1/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
General disorders Fatigue	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	100.0% 1/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	50.0% 2/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	58.3% 7/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	50.0% 5/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	42.9% 3/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	42.9% 3/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	60.0% 3/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	71.4% 5/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	42.9% 3/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	100.0% 3/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	57.1% 4/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	83.3% 5/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	23.1% 3/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
General disorders Influenza like illness	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
General disorders Infusion site swelling	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	100.0% 1/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
General disorders Non-cardiac chest pain	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	16.7% 2/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
General disorders Oedema peripheral	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	16.7% 2/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	16.7% 1/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	15.4% 2/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
General disorders Pain	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	20.0% 2/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
General disorders Pyrexia	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	100.0% 1/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	25.0% 1/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	42.9% 3/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	42.9% 3/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	28.6% 2/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	23.1% 3/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
General disorders Chest pain	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	16.7% 1/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
General disorders Malaise	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
General disorders Oedema	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
General disorders Peripheral swelling	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	16.7% 1/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Hepatobiliary disorders Cholelithiasis	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Hepatobiliary disorders Hepatic failure	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Hepatobiliary disorders Hepatic function abnormal	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Hepatobiliary disorders Hyperbilirubinaemia	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	16.7% 2/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	30.0% 3/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	28.6% 2/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	28.6% 2/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	16.7% 1/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Hepatobiliary disorders Jaundice	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	15.4% 2/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Hepatobiliary disorders Ocular icterus	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Immune system disorders Drug hypersensitivity	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	33.3% 1/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Immune system disorders Hypersensitivity	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Infections and infestations Epididymitis	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Infections and infestations Gastroenteritis viral	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Infections and infestations Nasopharyngitis	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Infections and infestations Oral candidiasis	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	16.7% 1/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Infections and infestations Oral herpes	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Infections and infestations Pneumonia	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	25.0% 1/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Infections and infestations Sinusitis	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Infections and infestations Upper respiratory tract infection	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	100.0% 1/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Infections and infestations Furuncle	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Infections and infestations Urinary tract infection	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	42.9% 3/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	23.1% 3/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Investigations Mean cell volume increased	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Infections and infestations Respiratory tract infection	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	33.3% 1/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Injury, poisoning and procedural complications Fall	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	100.0% 1/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Injury, poisoning and procedural complications Arthropod bite	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Injury, poisoning and procedural complications Incisional hernia	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Injury, poisoning and procedural complications Infusion related reaction	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	33.3% 1/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Injury, poisoning and procedural complications Radiation skin injury	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	16.7% 1/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Investigations Alanine aminotransferase increased	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	70.0% 7/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	57.1% 4/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	28.6% 2/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	40.0% 2/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	28.6% 2/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	71.4% 5/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	33.3% 1/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	28.6% 2/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	33.3% 2/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	76.9% 10/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Investigations Aspartate aminotransferase increased	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	90.0% 9/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	57.1% 4/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	42.9% 3/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	40.0% 2/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	28.6% 2/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	57.1% 4/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	28.6% 2/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	16.7% 1/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	84.6% 11/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Investigations Blood alkaline phosphatase increased	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	10.0% 1/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	38.5% 5/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Investigations Blood bilirubin increased	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	25.0% 3/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	40.0% 4/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	28.6% 2/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	57.1% 4/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	20.0% 1/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	57.1% 4/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	33.3% 1/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	61.5% 8/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Investigations Blood creatinine increased	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	25.0% 1/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Investigations Blood lactate dehydrogenase increased	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	50.0% 1/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Investigations Electrocardiogram QT prolonged	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	8.3% 1/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Investigations Gamma-glutamyltransferase increased	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	20.0% 2/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	28.6% 2/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	33.3% 1/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Investigations Lymphocyte count decreased	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	25.0% 1/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	7.7% 1/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Investigations Neutrophil count decreased	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Investigations Weight decreased	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	20.0% 1/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Investigations Weight increased	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	100.0% 1/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Investigations Hepatic enzyme increase	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Investigations Transaminases increased	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.
Investigations Blood urea increased	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/1 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/2 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/4 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/12 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/10 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/5 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/3 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	14.3% 1/7 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/6 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.	0.00% 0/13 • Part A: up to Safety follow-up (Week 124.9), Part A2: up to Safety follow-up ( Week 39), Part B1: up to Safety follow-up (Week 92.3) and Part C: up to Safety follow-up (Week 31.1) Part A, A2 and B1: The SAF included all enrolled participants who received at least 1 dose of study drug (either M4344 or carboplatin (Part B1 only) with the actual amount \> 0 mg. Part C: The SAF included all participants who received at least one dose of study drug. For Part A and B: MedDRA version 23.0 and for Part A2 and C: MedDRA version 24.0.

Additional Information

Communication Center

Merck KGaA, Darmstadt, Germany

Phone: +49-6151-72-5200

Email: service@emdgroup.com

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place

Restriction type: OTHER